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ABSTRACT: 
TITLE: FUNGAEMIA IN THE NEONATAL UNIT AT CHRIS HANI 
BARAGWANATH HOSPITAL: RISK FACTORS, AETIOLOGY, 
SUSCEPTIBILITY TO ANTIFUNGALS AND OUTCOME. 
 
Aim  
The aim was to determine the epidemiology of invasive fungal infections at Chris 
Hani Baragwanath Hospital. The specific objectives were to determine the 1) risk 
factors, 2) clinical presentation, 3) laboratory abnormalities, 4) organisms and their 
susceptibilities and 6) outcome in neonates with positive blood or CSF fungal 
cultures at Chris Hani Baragwanath Hospital.    
 
Methods 
This was a retrospective record review of patients who had positive blood or CSF 
cultures. Patients were identified by a computerized microbiological surveillance 
database. The data was collected over a three-year period from January 2002 to 
December 2004. Patient hospital files were reviewed for clinical signs, full blood 
count (FBC), C-reactive protein (CRP) and outcomes. Fungal culture results were 
reviewed for susceptibilities. To identify risk factors a convenient cohort was 
compared to the patients with fungal sepsis. The data was analysed using a 
Statistica software package. 
 
Results 
There were 150 patients with fungal sepsis among admissions over this 3 year-
period giving an incidence of 1.3 per 100 admissions. Thirty-nine records were not 
found thus 111 patient records were reviewed. The median birthweight was 1280g 
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and the gestational age 30 weeks. The median age of onset was 16 days and 
6.3% had early onset fungal sepsis. There were 61 males. Twenty-eight percent of 
patients were born to HIV positive mothers. Candida parapsilosis was the 
commonest (56%) organism isolated followed by C. albicans (43%). All the C. 
albicans isolates and 93% of the C. parapsilosis isolates were susceptible to 
amphotericin B.  Fluconazole susceptibilities were reported as, 96% for C. 
albicans, and 60% of the C. parapsilosis as being susceptible. Central venous 
catheters (CVCs) (p=<0.001), the use of TPN (p=<0.001) and third generation 
cephalosporins were identified as risk factors associated with fungal sepsis. The 
all-cause  mortality and Candida–related mortality were 30% and 23% 
respectively. The non-survivors had lower platelet counts (p=0.007) than the 
survivors. Patients with Gram-negative sepsis had lower platelet counts than the 
fungal group (p=<0.001) on the repeat laboratory parameters. 
 
Conclusion 
 
The incidence is 1.3 per 100 admissions. Risk factors associated with fungal 
sepsis are very low birthweight and gestational age, the use of TPN, CVCs and 
third generation cephalosporins. Candida parapsilosis is the common organism 
causing fungal sepsis in neonates. Candida albicans was associated with a higher 
mortality. Thrombocytopenia is not organism specific to fungal sepsis. 
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PREFACE 
 
Advances in neonatal care have escalated dramatically. With the VLBW infant 
surviving longer and having prolonged hospital admissions, Candida is emerging 
as an important pathogen. Candida is associated with a significant morbidity and 
mortality. This study was undertaken as I had noticed a trend towards an increase 
in the number of yeasts being isolated in the unit. A study to look at the 
epidemiology of Candida had not been undertaken in the neonatal unit in the Chris 
Hani Baragwanath Hospital.   Hence, it was imperative to outline the patient 
characteristics, risk factors, susceptibilities and outcome of the patients with 
Candida sepsis. The information attained would assist us as clinicians to improve 
the quality of care and the current management of patients with Candida sepsis 
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CHAPTER 1  
LITERATURE REVIEW 
1.1 Background  
 
The World Health Organization (WHO) reports that 10 million children under the 
age of 5 years die each year.1 The mortality rate of children under the age of 5 
years in Sub-Saharan Africa is 164 per 1000 and in South Africa is 67 per 1000 
live births.2  Neonatal deaths accounts for 30-40% of these under 5 deaths.1 In 
Sub-Saharan Africa the neonatal mortality rate was reported to be 42-49 per 1000 
live births in the year 2000. In the developing world 1.6 million of neonatal deaths 
are due to neonatal infections.1 One of the Million Development Goals (MDG) is to 
reduce under-5 mortality rate by 66% by the year 2015.3 Therefore, as part of the 
process of achieving this goal of reducing neonatal deaths especially those due to 
neonatal infections; it is important to understand the epidemiology of neonatal 
infections. This would include identifying the risk factors and causes of these 
infections.        
    
Neonatal infection can be classified as congenital or acquired. In the acquired 
group it can be sub-divided into early-onset sepsis (EOS) (infections occurring 
within the first 72 hrs of life) and late-onset sepsis (LOS) (infection occurring after 
72 hrs in hospital.4,5 Sepsis is defined as the isolation of an organism from a blood 
culture taken from a neonate with signs and symptoms of an infection.5,6 The signs 
of infection are often non-specific during the neonatal period. The diagnosis of 
sepsis is often made on clinical suspicion. The National Institute of Child and 
Human Development (NICHD) Neonatal Network and other studies have reported 
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that the most common signs of sepsis are apnoea (55%), gastro-intestinal tract 
(GIT) symptoms (46%), increased need for oxygen and ventilatory requirements 
(36%), lethargy and hypotension (25%).5,7-9 The blood culture is the gold standard 
for the diagnosis of sepsis.4 The blood culture is not as sensitive for fungal 
elements as it is for bacterial pathogens therefore; fungal elements take longer to 
culture10. The full blood count (FBC), C-reactive protein (CRP), Interleukin 6 (IL-6), 
Interleukin 8 (IL-8) and procalcitonin are other useful laboratory tests that are used 
to assist in diagnosing infection.4,11    
 
Infections due to invasive fungal infections account for 15% of all blood stream 
infections (BSI) in the neonatal intensive care unit (ICU).12 Candida albicans is the 
most frequently recovered fungus, but in the last two decades the trend has 
changed with C. parapsilosis as the more prevalent organism. As invasive 
candidemia is associated with an attributable mortality of 38% and a crude 
mortality of 30%-75%; emphasis has been placed on identifying risk factors and 
empirically treating patients whilst awaiting results.10 In this review and report I am 
focusing mainly on Candida infections, looking at the pathogens, presenting signs 
and symptoms, risk factors, treatment and mortality associated with Candida 
infections.  
 
1.2 Candida species causing infections in neonates  
 Candida is the genus commonly isolated in neonates. Candida organisms are 
yeasts and exist in a unicellular form. They are ovoid and thin-walled and 
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reproduce by budding.13,14 Candida organisms grow well in blood culture bottles 
and agar and do not require special fungal media. They form smooth, creamy 
white glistening colonies and resemble staphylococcal colonies.15 To further 
identify the organism as a yeast, one can facilitate germ tube formation by placing 
the organism in serum and within 90 minutes germ tubes are formed. Metabolic 
tests can be utilized to speciate the organism.15,16 This is based on physiologic 
parameters rather than morphologic characteristics. They stain as gram positive 
on haematoxylin and eosin stains. Potassium hydroxide (10%) solution can be 
used to facilitate hyphae and pseudohyphae formation.15,16,17 
  
Candida species is a normal commensal in humans. It is commonly found on skin, 
throughout the gastrointestinal tract (GIT), in sputum and the female genital 
tract.16,17 Candida albicans is found in soil, in animals, in hospital environments, 
inanimate objects, and food. The non-albicans Candida species live in animal and 
non-animal environments.18 Candida species isolated from blood or sterile fluid 
(cerebrospinal fluid, pleural and peritoneal fluid, and urine aspirates) should be 
considered a pathogen regardless of whether the host is immunocompetent or 
immunodeficient. Rarely is Candida species a laboratory contaminant. 
 
There are more than 150 Candida species but only 15 cause disease in 
humans.14,19 These include C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, 
and C. krusei, C. guilliermondii, C. dubliensis, C. rugosa and C. lusitaniae. 
Candida albicans has been reported in many studies as the commonest Candida 
species. Candida parapsilosis, C. glabrata, C. tropicalis, and C. krusei are among 
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the common non-albicans Candida (NAC) species. Candida guilliermondii, C. 
dubliensis, C. rugosa and C. lusitaniae are the less common NAC species.20 
Ninety-seven percent (97%) of candidemia is caused by C. albicans, C. 
parapsilosis, C. tropicalis, C. glabrata, and C. krusei.15,16,18 
 
In neonates the two commonest causes of candidaemia are C. albicans and C. 
parapsilosis. In the last two decades there has been a decrease in C. albicans and 
a proportional increase in the non-albicans Candida (NAC) species causing 
invasive disease.20-22 Kosshoff et al reported a 60% increase in the prevalence of 
C. parapsilosis over a 5-year period 1991-1995.23 The reasons for the shift in an 
increase in NAC include the use of prophylactic azoles, the HIV epidemic and the 
use of fluconazole for oropharyngeal and oesophageal candidiasis.22,24 In Pfaller’s 
study a geographical as well as an interhospital variation with respect to species 
isolation and a susceptibility pattern was found.25-27 In the USA and South 
America, Pfaller reported that C. albicans isolates (53.3%) were more prevalent 
than NAC (43.8%) differing from Canada where 50% of all the isolates were due to 
NAC.25 Of the NAC isolates in Canada, C. parapsilosis was the commonest 
Candida species isolated. There was also a difference in species isolated from 
different groups of hospitalized patients. In neonates the commonly isolated fungi 
are C. albicans and C. parapsilosis, whereas patients with haematological 
malignancies and those with solid tumors are often infected by C. krusei, and C. 
tropicalis and C. glabrata respectively.14,22,26-28  
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1.2.1 Candida albicans 
Candida albicans is the most common species (50-70%) isolated in neonates; 
followed by C. tropicalis, C. parapsilosis and C. glabrata.17,29 It is more virulent 
than C. parapsilosis. It is a normal commensal of the female genital tract and 
accounts for most of the early–onset fungaemia in the neonate. It is associated 
with a higher mortality (44.8%) compared to C. parapsilosis which has been 
reported to have a mortality rate of 28.5%.30 This is accounted for by its virulence 
factors. Being a normal commensal of skin it stands to reason that any breach in 
the skin barrier leads to seeding and the development of invasive disease. It has a 
cell envelope that has molecular adhesions that bind it to host epithelial surfaces.31 
It has a rapid germination upon seeding into the bloodstream, secretes proteinase, 
form true hyphae, resists phagocytosis and adheres to host surfaces.29  
 
It is an aerobic yeast that can exist anaerobically. It grows into two main forms 
budding yeast or as continuously extending hyphae with pseudohyphae as an 
intermediate form. It is naturally diploid and has no known sexual cycle. Candida 
albicans has been regarded as the dominant Candida species but in the last two 
decades is being replaced by C. parapsilosis as the common species in the 
neonatal population. 
 
1.2.2 Candida parapsilosis 
It is the second most common cause of fungal sepsis in neonates and infants.32,33 
The cells are oval, round or cylindrical in shape on Sabouraud’s agar. The 
colonies are creamy, white, shiny, smooth or wrinkled.34 Candida parapsilosis do 
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not have true hyphae but pseudohyphae and can exist in the yeast form as well. It 
is a normal commensal of skin and its pathogenicity is limited by an intact skin 
barrier. It can spread nosocomially by hand carriage of health care workers.35 
 
Its incidence varies with geographical region.27 In the United Kingdom C.  
parapsilosis accounts for one quarter36 of invasive fungal infections in ill neonates 
whereas it accounts for one third of bloodstream infections in the United States.37 
It has emerged as one of the predominant fungal pathogens in the NICU and is 
associated with an increased mortality. It can occur without prior colonization; it 
grows easily in total parenteral nutrition (TPN) and forms biofilms on 
catheters.34,38,39  
 
Unlike C. albicans, C. parapsilosis organisms are not commonly found in the 
vaginal tract. The hands of health care workers (HCW) are a major vector coupled 
with poor hand hygiene and hand washing techniques.27,32,35 The virulence factors 
include slime production. This causes cell surface hydrophobicity and co-
adherence among yeast cells. This leads to aggregation on epithelial cells. They 
form biofilms on devices and this renders them impermeable to antifungals.27,40 
They secrete enzymes e.g. aspartic proteinases that facilitate invasion and 
colonization of host tissue; phospholipases that disrupts the host membrane, 
lipases that digest lipids for nutrition and adheres to host cells and tissues.34  
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1.2.3 Candida krusei 
Candida krusei is one of the NAC that is increasing as a human pathogen. It is 
isolated from natural habitats and is a transient commensal in man. It has been 
isolated from mucosal surfaces (oral, GIT, vaginal and anorectal) in healthy 
individuals. It is commonly isolated from patients who are severely 
immunocompromised and who have haematological malignancies.41,42 It is one of 
the three most common yeast combinations isolated with C. albicans in dual 
Candida infections. The other two being C. glabrata and C. tropicalis. It has the 
appearance of long grain rice. It grows on Sabouraud’s agar as spreading colonies 
with a rough, whitish yellow surface. Its cell wall has low reactivity with antisera 
against other Candida species. It is less virulent than C. albicans and is weakly 
immunogenic. It is found in two basic forms, yeasts and pseudohyphae and they 
exist together in growing cultures. C. krusei can grow in vitamin-free media at a 
temperature of 43-45 degrees Celsius. 
 
It is less invasive than C. albicans. Candida krusei do not adhere to and penetrate 
epithelial cell surfaces as well as C. albicans. It adheres more to inert surfaces 
than buccal mucosa and therefore has a predilection for implants and catheters. 
Its biofilm formation is more extensive than any other species because it has 
increased cell surface hydrophobicity and increased adherence to inert plastic. It 
does not produce hydrolytic enzymes. Candida krusei is more susceptible to killing 
by polymorphonuclear cells, macrophages and other immunoeffector cells than C. 
albicans.  
 
  
8 
 
1.2.4 Candida glabrata  
The high prevalence of HIV and AIDS resulting in the long term use of fluconazole 
has lead to the selection of C. glabrata infection.24,38,40,43,44 Candida glabrata like 
C. krusei is low in virulence. The lack of hyphae is a factor in this regard. It 
produces proteinase enzymes and has cell surface hydrophobicity that is similar to 
C. albicans. It does not possess the B-integrin binding receptor therefore; it is less 
adherent to epithelial cell surfaces than C. albicans. It does not exhibit phenotypic 
switching like C. albicans. Host defences do not have to be that stringent in 
combating C. glabrata because it is less virulent. Risk factors that predispose to C. 
glabrata infections include prolonged hospitalization and prior antimicrobial use 
and increased colonization in immunocompromised patients.21 In addition to the 
other risk factors that predispose to Candida infections, there is an increase in 
incidence because of prior azole exposure.22,38 It has become an important 
pathogen because it has decreased susceptibility to antifungal agents.20 It causes 
infection in any organ and therefore has a diverse clinical picture. C. glabrata 
candidemia can present with a low grade fever to fulminant septic shock. It has a 
higher mortality than C. albicans but this is attributed more to host factors than 
virulence of the organism.44 
 
1.3 Incidence 
Fungal sepsis is becoming an increasingly important pathogen in the neonatal 
intensive care units.45 It is the third most common cause of nosocomial 
bloodstream infection in the United States.14 It affects up to 3000 infants each year 
in the United States.19,46  
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The frequency has increased by eleven fold in some institutions. In a study by 
Kossoff et al over a fifteen year period; from 1981 to 1995, the incidence had 
increased from 2.8% to 28%.23 The NICHD Neonatal Network had also reported 
that the incidence of all late onset sepsis due to Candida had increased from 9% 
to 12%.47,48 Chapman has observed the incidence to range from 2.2% to 12.9% in 
the very low birth weight  (VLBW) infant  and from 5.5% to 16.5% among the 
extremely low birth weight infant (ELBW).49,49,50 An overall incidence of 12.3 per 
1000 admissions has been reported.7 The overall incidence varies from institution 
to institution.   
 
1.4 Risk Factors 
1.4.1 Intrinsic Factors 
It has been well documented that very low birth weight infants are at increased risk 
of developing candidiasis due to the increase in the fungal burden or colonization 
in this population.4,35,51 The incidence has been reported as 4-15% in the ELBW 
infant.10,45,51,52 Gestational age has been reported to be inversely associated with 
Candida sepsis.53  
 
 As early as 1986 Bayley et al found that 7.7% of colonized infants developed 
systemic fungal disease.54 A Taiwanese group documented a 22% fungal 
colonization rate within two weeks after birth and reported that one fifth of 
colonized infants will develop invasive disease. This is another risk factor for 
fungal sepsis.7,55 Host factors such as immaturity of the immune system and the 
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infant’s fragile skin and mucous membranes play a role in the development of 
fungal sepsis.35 The mucous membrane defenses are decreased in the VLBW 
infant. The breakdown of skin through the insertion of the central venous catheter 
per se is an independent risk factor.14 Firstly there is a breach of the skin. 
Secondly, the organism forms a biofilm which surrounds the catheter. The 
Candida organism harbors itself within the biofilm thus protecting itself from the 
antifungals.  
 
The neonate has an altered innate or adaptive immunity.14 Serum complement 
levels, fibronectin, and defenses and cytokine production are decreased in all 
newborns; in premature babies to a greater degree than the term infants.18 There 
is a limited production of antibodies in response to the invading pathogen. Cellular 
defenses such as chemotaxis, phagocytosis and microbiological killing are 
relatively impaired.11 The use of intralipid as a feeding modality further decreases 
the chemotactic ability of the neonatal leukocytes. This renders the premature 
infant more susceptible to infections and leads to, dissemination and deep-seated 
tissue infections.7 Maternal IgG transfer usually occurs in the third trimester and 
confers some immunity on the neonate.11,56 Thus, in a premature baby there is a 
limitation on passively acquired immunity.37   
 
1.4.2 Extrinsic Factors 
The other risk factors include the use of H2 blockers, indomethacin, steroids and 
antibiotics especially carbepenems and third generation cephalosporins.4,57,58 The 
introduction of foreign bodies like the use of instrumentation such as endotracheal 
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intubation (ETT), central venous catheters (CVCs), umbilical venous or arterial 
catheters and nasogastric tubes in sick neonates are other risk factors.17,35,52,53,59 
The length of stay in the neonatal unit exposes these infants to nosocomial 
bacterial infections therefore increasing the need for venous access to administer 
antibiotics especially third generation cephalosporins.31,60 Feeding intolerance and 
the use of intralipid solutions make these infants more susceptible to 
candidemia.40,61 Total parenteral nutrition (TPN) mainly intralipid acts a good 
medium for fungal elements to grow. Abdominal surgery has also been identified 
as a risk factor.32,51,52   
 
1.5 Clinical Presentation and Laboratory Findings 
Patients with invasive Candida infections can present with non-specific signs of 
infection. The clinical manifestations range from temperature and glucose 
instability, respiratory distress, increase in oxygen requirements, features of 
necrotizing enterocolitis (NEC), feeding difficulties, lethargy, abdominal distension 
and vomiting.17 This makes it difficult to identify whether the offending pathogen is 
a fungal organism or a bacterial organism. This often results in delays in starting 
the appropriate treatment.57  
 
Among the laboratory parameters a high C-reactive protein and 
thrombocytopenia62 are features that have been identified to be associated with 
Candida infections.17,57  Positive blood cultures and cultures from other sterile sites 
are a gold standard to diagnose invasive Candida infections.17. However, blood 
culture has a low yield; between 50-80% for a positive fungal result.14,19,57 The 
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yield on the blood culture also takes a long time, as the organism is slow growing 
and may take a while before it becomes positive.37 At least 30 % of neonates are 
diagnosed with invasive candidiasis at post mortem. Newer methods to diagnose 
fungal infections have been formulated and are currently being tested. This 
includes B-D glucan test, breath test, and growth on a special broth.   
 
Because of the difficulties in making a diagnosis of fungal sepsis, Benjamin et al 
has developed a scoring system looking at the gestational age and other risk 
factors. The clinical predictive score is based on the probability of developing 
fungal infection when a patient has these risk factors.10 A score of 0, 1 or 2 is 
assigned based on risk factors such as decreased gestational age, 
thrombocytopenia and the use of third generation cephalosporins. If the neonates 
were thrombocytopenic a score of 2 was assigned (otherwise 0), if they received a 
3rd generation cephalosporins or a carbepenem a score of 1 was assigned 
(otherwise 0), if the gestational age was 25-27 weeks a score of 1 was assigned 
(otherwise 0), if the gestational age was <25 weeks a score of 2 was assigned. If 
the combined score was 2 or more it was regarded as a positive candidemia 
score. A score >2 has a sensitivity of 85% and a specificity of 47%. Once a patient 
meets these criteria antifungal treatment would be started empirically.  
 
1.6 Treatment 
The treatment modalities are limited but newer drugs are being formulated and 
there are some trials that are being conducted. The treatment is limited and is 
fraught with its own complications depending on the organism’s sensitivity 
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patterns, the patient’s medical condition and the epidemiology of the strains in the 
NICU. Polyenes (Amphotericin B), azoles (fluconazole, voriconazole, itraconazole, 
miconazole) and fluorinated pyrimidines (flucytosine), echinocandins (caspofungin, 
micafungin) are among the armamentarium used to treat candidemia.17,50,63 The 
antifungal agents most commonly used are amphotericin B and fluconazole, 
therefore the next two sections will review these two drugs. 
 
1.6.1 Amphotericin B 
The gold standard of therapy for candidiasis is amphotericin B.17 It was first 
formulated in the 1950s. Amphotericin B is fungicidal. It binds to the ergosterol 
component of the fungal cell wall; this then leads to membrane leakage and 
eventually cell death.50,64 Its use is limited by its safety profile. It causes 
nephrotoxicity and hepatotoxicity. It is often used empirically for suspected 
systemic candidiasis.63  
 
It is sometimes used in combination with fluconazole for treating refractory 
candidiasis.65 Some studies show antagonism between the two drugs but clinically 
these drugs are synergistic with a positive reponse.63,66,67 It is also used in 
combination with flucytosine to treat meningitis due to candidiasis.65 
 
Amphotericin B comes in different forms namely Amphotericin B lipid complex 
(ABLC), Amphotericin B colloid dispension (ABCD), liposomal Amphotericin B (L-
AmB). These lipid formulations have similar efficacy and a better side-effect profile 
than the standard amphotericin B.30,68-70 The other advantage is that higher doses 
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can be used.71,72 Their use has been advocated in renal failure and when there is 
failure of standard amphotericin B treatment.30,50,73,74 Lipid formulations are better 
if given as first line antifungal treatment and at high doses.17 Study by Linder has 
demonstrated a shorter duration of antifungal therapy with lipid formulations and 
that there is a better eradication of the organism.60 Liposomal AmB has the 
greatest renal protection of the three lipid formulations.63,70 Despite its high side-
effect profile, amphotericin B is the gold standard of treatment for invasive 
candidiasis.63,75 
 
1.6.2 Fluconazole  
Fluconazole is an azole that was developed in the 1970s. It acts by inhibiting CYP-
dependent 14-α-demethylase.50 This inhibition interrupts the conversion of 
lanosterol to ergosterol. Ergosterol is a major component of the fungal cell wall.64 
This then increases membrane permeability and leads to cell leakage and 
eventually cell death. It also leads to cell growth inhibition, morphologic changes, 
cessation of sterol synthesis, and reduction in adhesion to epithelial cells. 
Fluconazole is fungistatic and not fungicidal. It has good penetration into 
cerebrospinal fluid (CSF), liver, kidney and spleen. It is excreted unchanged in the 
urine therefore it is a good agent for treating UTI (urinary tract infections). 
Fluconazole is as effective as amphotericin B and it has less toxicity therefore is a 
safer alternative to amphotericin B in treating candidiasis.76 Driessen et al has 
reported that fluconazole has the same efficacy in clearing the infection as 
amphotericin B.77 Some centers use fluconazole as a first line agent as empiric 
therapy because of its low side effect profile and excellent oral bioavailability.78 
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Most Candida species are susceptible to fluconazole, but C. glabrata is dose-
dependent and C. krusei is resistant.78-80 However, resistance to fluconazole has 
been reported. This is due to the HIV epidemic which has resulted in the 
widespread use of fluconazole to prevent and treat candidiasis. This has lead to 
more non-albicans Candida (NAC) species such as C. glabrata and C. 
guilliermondii becoming resistant to fluconazole.21,40,43 Fluconazole has been 
shown to reduce the incidence of colonization and invasive candidemia when used  
as a prophylactic agent.81-84  
 
 There has been a concern in the emergence of Candida strains (C. krusei and C. 
glabrata) that exhibit resistance to fluconazole.85 This has been thought to be due 
to the use of fluconazole for prophylaxis in neonates at risk of invasive fungal 
sepsis. Many studies have documented no resistance to fluconazole in patients 
that have received prophylaxis.81-83 Kauffmann et al has speculated that with the 
lower dose and less frequent dosing schedule resistance may be prevented.83 
However, resistance can develop over time in a population that has received 
fluconazole.60,86  
 
A recent Cochrane meta-analysis has shown a decrease in fungal infections with 
fluconazole prophylaxis in VLBW infants.87,88 Recommendations are that high risk 
populations should receive prophylaxis. The low dose and shorter dosing schedule 
should preclude from the development of resistant strains. Caution should still be 
exercised as the threat of resistance is ever looming. 
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 Antifungal prophylaxis decreases the fungal burden and thereby decreases the 
incidence of colonization and invasive candidiasis.89 Manzoni and others had 
shown that this strategy is effective in decreasing invasive Candida infections in 
the neonatal population.84 However, the development of NAC strains and resistant 
Candida strains is still an ever looming problem.21 
 
1.6.3 Combination therapy 
Amphotericin B and flucytosine has been the first combination used for meningitis, 
endocarditis, and peritonitis caused by Candida.90 The use of fluconazole and 
amphotericin B has shown antagonism in vitro but clinically these drugs are 
synergistic with a positive response.63,65 A study by Rex et al has shown 
favourable outcomes.91 There was a success rate of 68% vs 56% when 
amphotericin B and fluconazole were used in combination than when fluconazole 
used alone. The mortality was the same in both groups. Thus, amphotericin B and 
fluconazole are used in combination to treat refractory candidiasis. There is very 
limited data on the use of echinocandins in combination with amphotericin B.65 It 
should have an additive effect and synergistic effect as caspofungin inhibits the 
cell wall synthesis and enhances the access of amphotericin B to its target which 
is the cell membrane.92  
 
1.6.4 Empiric therapy 
Fungal sepsis is a leading cause of mortality and morbidity but this is organism 
specific. Empiric therapy has been shown to decrease the mortality and morbidity 
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in at risk patients. Most of the studies have been in adult cancer patients with a 
febrile illness and neutropenia.93 The choice of antifungals range from 
amphotericin B to voriconazole. Amphotericin B is the most efficacious empiric 
antifungal used but it is quite toxic.94 Comparative studies have shown that the 
efficacy decreases with the other classes of antifungals but the side effect profile 
improves. Kaufman and Fairchild have identified high-risk ELBW infants with risk 
factors such as CVCs, ETT in-situ, platelet count <100 000/mm3, broad spectrum 
antibiotics, exposure to carbepenems and cephalosporins and a gestational age 
less than 28 weeks as a subset of patients that would benefit from empiric 
therapy.7,38,95,96  A Candida clinical predictive model has been devised to assist in 
commencing empiric therapy as fungal elements take a long time to grow.10 The 
duration of empiric treatment would be for as long as the blood culture is formally 
interpreted as negative i.e. if a blood culture is regarded as negative after seven 
days then empiric therapy would be continued for seven days.7 In some 
institutions, if a patient is not responding to antibacterial treatment, and has one or 
more of the risk factors and/or features suggestive of a fungal infection; antifungal 
therapy would be commenced empirically. The choice of drug would depend on 
the epidemiology of Candida isolated in the NICU, the patient population and the 
medical condition of the patient10 and whether the patient received fluconazole 
prophylaxis or not. If fluconazole prophylaxis is practiced in the unit then an 
antifungal other than fluconazole should be commenced as empiric treatment.  
Cross resistance as well as co-resistance to azoles are confounding variables. 
Non-albicans Candida isolates are also emerging as important pathogens21 thus, 
the choice an antifungal as empiric therapy may be difficult.   
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1.7 Susceptibility of Candida Species to Antifungals 
1.7.1 Susceptibility to Amphotericin B 
Susceptibilities are carried out by detecting the minimum inhibitory concentrations 
(MIC) of the particular organism to an antifungal.97 The MIC is defined as the 
lowest concentration of amphotericin B and fluconazole to reduce the turbidity of 
cells to >95% and 50%. For fluconazole if the MIC < 8ug/l the organism is 
classified as susceptible(S); and if the MICs are > 64ug/l the organism is classified 
as resistant (R). If the organism has an MIC between 16 and 32 ug/l it is classified 
as susceptible dose-dependent (S-DD), which means that at a higher dose of the 
antifungal the organism would be rendered dead. In the case of amphotericin B an 
MIC of <1ug/l is susceptible (S) and resistant as an MIC >2 ug/l.96,97,98  
 
Ninety-five percent (95%) of C. albicans isolates are susceptible to amphotericin 
B, whilst 97-98% of C. parapsilosis isolates are susceptible.95,99 Clerihew has 
reported that all C. parapsilosis isolates in her study are sensitive to amphotericin 
B.36 Candida glabrata and C. krusei isolates are relatively resistant to the 
amphotericin B.25,95  These two organisms have higher MICs for amphotericin B67 
and thus, the IDSA guidelines recommends a higher dosage of amphotericin B 
when treating them.63,66 Yang and  Shoa  in Taiwan and Almirante in Spain have 
reported similar findings.79,100,101  It has also been reported that there is an 
emerging resistance of C. tropicalis and C. guillermondii to amphotericin B.38,99,102, 
whilst C. lusitaniae  isolates are resistant to amphotericin B.78  
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1.7.2 Susceptibility to Fluconazole 
Most C. albicans isolates are sensitive to fluconazole103,104  whereas the NAC tend 
to have higher resistance rates to fluconazole.25,43,85,102,105  In China Ying Liang 
Yang et al found that all C. parapsilosis isolates were sensitive to fluconazole and 
the C. krusei isolates having had the highest resistance rate to fluconazole.79,106 
Nine percent (9%) of C. glabrata and 100% of C. krusei isolates have been 
reported to be resistant to fluconazole.25,31,104 Newer triazoles have been 
developed but the C. glabrata isolates had shown cross resistance to the triazoles 
hence, amphotericin B was used as  therapy for this isolate. With the increased 
use of amphotericin B the resistance rates of C. glabrata isolates were reported as 
high as 20-36% in North America. Co-resistance to amphotericin B and 
fluconazole by this isolate may be an impending problem.79 Thus, it is wise to 
monitor surveillance patterns so that emerging co-resistance can be identified and 
an appropriate antifungal is chosen as empiric therapy. 
 
Azole prophylaxis has been implicated as causing a shift towards an increase in C. 
krusei and C. glabrata infections.21,100,103,107 These strains are known to be 
inherently resistant to fluconazole. Whilst the overall incidence of candidemia is 
decreasing as azole prophylaxis decreases the rate of C. albicans infections there 
is an increase in infections with NAC species.40 There should be an awareness 
when using fluconazole as empiric therapy in centers where fluconazole is used as 
a prophylactic agent.104 
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Sarvikivi has shown the emergence of a resistant C. parapsilosis strain to 
fluconazole.86 This had occurred in patients in Finland that received fluconazole 
prophylaxis at the time that the blood culture was taken. This is in contrast to other 
studies that have proven that C. parapsilosis remains sensitive to fluconazole 
despite the patients having received prophylaxis. Therefore one needs to bear in 
mind that resistance can develop over time. 
 
1.8  Mortality 
The mortality rate is 20 – 40% and it depends on the Candida 
species.8,9,14,47,51,57,63 The highest mortality is reported as being due to C. albicans 
among those with fungal sepsis.30,47,75 This was noted by Faix in a single centre 
study with C. albicans accounting for 24% of the deaths and while there were no 
deaths in those with C. parapsilosis.108 The NICHD Neonatal Network had also 
reported a significantly higher mortality (44%) due to C. albicans compared to 16% 
of those with C. parapsilosis.47 This is also attributed to the timing of the infection. 
Candida albicans is vertically transmitted causing sepsis early in the more 
compromised host and C. parapsilosis causing infection in the older more immune 
competent host.7-9,109 The crude mortality of C. glabrata and C. krusei is reported 
as 50% and 100% respectively110. In a study by Pappas and Rex the Candida-
specific mortality in patients <13years for C. glabrata was 13% for Candida-
specific mortality and 0% for C. krusei. This study also found that the survival rates 
were not any worse for C. glabrata isolates as compared to the other Candida 
species. If the patients with C. glabrata isolates were not treated it was associated 
with a lower survival rate compared to those who received treatment.111 
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CHAPTER 2 
2. OBJECTIVES AND METHODS 
2.1 Objectives 
The objective for this study was to determine the epidemiology of invasive culture 
proven fungal infections at Chris Hani Baragwanath Hospital.  
The specific objectives were to determine 
1. the risk factors associated with fungal sepsis 
2. clinical presentation of neonates with fungal sepsis 
3. laboratory abnormalities in infants with fungal sepsis 
4. the Candida species causing infections in neonates,  
5. Susceptibilities of Candida species to commonly used antifungal agents 
6. the mortality rates among neonates infected with Candida 
 
2.2 Methods 
2.2.1 Study Design 
This was a retrospective record review. Patients were identified by a computerized 
microbiological surveillance database. Once identified the patient records were 
retrieved and analyzed. The data was collected over a three year period from 
January 2002 to December 2004. To identify the risk factors a control group was a 
convenient sample which was from records of patients who had culture proven 
Gram negative (GN) sepsis collected over the same time period. 
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 2.2.2 Study Population 
Patients who had positive blood and /or CSF cultures were identified through 
looking at the laboratory database. Patient’s hospital records were retrieved for 
data collection. The data was collected with the aid of a data collection sheet 
(Appendix A). This sheet included section 1 which concentrated on both infant and 
maternal demographic data; section 2 dealt with the infective demographics and 
section 3 was dedicated to the infants’ presentation at the time of sepsis. This 
included details such as the laboratory parameters full blood count (FBC), C-
reactive protein (CRP) and blood culture, and cerebrospinal fluid (CSF) results 
both at the time of presentation and repeat results. Repeat results were the very 
next laboratory parameters (FBC, CRP blood and CSF culture) sampled from the 
same patient around the time of infection. It also included details of antibiotic 
usage, the use of central lines, and total parenteral nutrition. The details of the 
organism and its susceptibilities were also collected. Data on the outcome that is 
whether the patient died secondary to fungal sepsis was collected. Death due to 
fungal sepsis was defined as a patient having demised within two weeks of the 
positive fungal culture. Antifungals that were used in the unit during this period 
were amphotericin B and fluconazole. Ethics approval was obtained from the 
University of the Witwatersrand Committee for Research of Human Subjects. 
 
2.2.3 Determining Risk Factors 
To determine the risk factors for the development of fungal sepsis, data from 
infants who were infected with Gram-negative organisms were used for 
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comparison. The Gram-negative cohort was a convenient sample as data had 
already been collected for another study.  
 
2.2.4 Statistical Analysis 
The information was entered onto a computer database and analyzed using the 
Statistica statistical software package. Mean and standard deviations were used to 
describe data with normal distribution and medians and 25th and 75th percentiles 
were used to describe data without normal distribution. Comparison between 
categorical variables was performed using the Chi-squared or Fisher exact test. 
Comparison between continuous variables was performed using a Students’ t-test 
when there was a normal distribution otherwise a Mann-Whitney U test was used. 
A significant difference was taken as a p-value of less than 0.05.  
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CHAPTER 3  
3.  RESULTS 
3.1 Incidence 
One hundred and fifty (150) patients were identified to be infected by Candida 
from January 2002 to December 2004. There were 11589 admissions to the 
neonatal unit over this three year period. This gave an incidence of 1.3 cases of 
Candida per 100 admissions. Patient hospital records of 39 patients were not 
found leaving 111 infants for analysis.  
 
3.2 Characteristics 
Characteristics of the 111 infants that had their hospital records reviewed are 
shown in Table 3.1. Ninety percent of the patients reviewed were low birthweight 
(LBW) and premature, with a median birthweight of 1280g and a gestational age of 
30 weeks. Seventy-three percent (81/111) of the patients were VLBW 
(weighing<1500g).  Fifty-nine percent (59%) of the patients were born vaginally 
and in 93 patients (84%) the maternal HIV status was known. Of those with known 
HIV status 28% were born to mothers who were HIV positive. The median age of 
onset of patients who had positive Candida cultures was 16 days, and 6.3% of 
patients were less than 3 days old. 
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Table 3.1 Characteristics of Infants with Fungal Sepsis 
    
Birth Weight (g)*                                       1280 (660-3300) 
Gestational Age (weeks)*                                        30 (23-40) 
Mode of delivery   
    Vaginal                                               66 (59%) 
    Abdominal                                             35 (32%) 
Maternal HIV Status   
    Positive                                                                 31 (28%) 
    Negative                                                                62 (56%) 
    Unknown                                                              18 (16%) 
Apgar   
    1 minute                                                                  7 (1-10) 
    5 minutes                                                               8 (4-10) 
Gender (n=111)   
   Female                                                                   49 (44%) 
   Male                                                         61 (55%) 
   Not specified                                                           1 (1%) 
Age at onset (days)                                       16 (1-86) 
* Median (Ranges)  
  
 
3.3 Clinical Presentation and Diagnosis 
The common presenting signs were related to the respiratory system. The three 
most common presenting symptoms were an increase in the ventilatory 
requirements, temperature instability and abdominal distension (Table 3.2). Most 
of the patients were diagnosed as having candidemia as there was no specific 
clinical diagnosis given. These patients had clinical signs and a positive Candida 
culture. The common clinical diagnosis was NEC (35%). This is a primary 
diagnosis. The patients presented with NEC and subsequently developed fungal 
sepsis. 
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Table 3.2  Presenting Signs and Clinical Diagnosis in Patients  
                 with Fungal Sepsis 
 
 
  
n (%) Signs              
General (n=49)  
        Temperature instability 42 (22) 
        Lethargy    5 (2.6) 
Gastrointestinal tract (GIT) (n=42)  
        Abdominal distension 22 (11) 
        Nasogastric aspirates          14 (7) 
        Vomiting 6 (3) 
Respiratory (n=84)  
        Apnoeas     21 (11) 
        Respiratory distress and/or desaturating 63 (33) 
Metabolic (n=18)  
        Hyperglycaemia 13 (6.6) 
        Hypoglycaemia    5 (2.6) 
Central nervous system (CNS) (n=2)  
        Seizures 2 (1) 
  
Diagnosis (n=111)  
        Candidemia 54 (49) 
        Necrotizing Enterocolitis 39 (35) 
        Nosocomial Pneumonia 14 (13) 
        Meningitis  7 (6) 
    
 
 
3.4 Laboratory Findings 
Most patients (98%) had a full blood count (FBC) and CRP done as part of the 
work-up at the time of sepsis. The majority (82%) of patients had a normal white 
cell count (WCC) with only 7(6%) having leucopenia (WCC <5 x 109/l) and 13 
(12%) having a leucocytosis (WCC >25x109/l) (Table 3.3). Fifty-six percent of 
patients had a thrombocytopenia (platelet count <150x109/l). Seventy-three 
percent of patients had an abnormal CRP with 66% having a CRP of > 20mg/l.    
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Table 3.3 Initial and Repeat Laboratory Findings (FBC and CRP) Among  
                Infants with Fungal Sepsis     
 Initial Repeat  
 n=109 n = 99 
White cell count*                     13.3 (1.5-57.1)         12.8(2.6-43.5)  
         Leucopenia (< 5 x 109/l) 7 (6%) 10 (10%) 
         Normal ( 5-25 x 109/l) 89 (82%) 76 (77%) 
         Leucocytosis (>25 x 109/l)   13 (12%) 13 (13%) 
  
 
 n=109 n = 99 
Platelet count*     123 (5-755) 92(4-721)  
        Thrombocytopenia (<150x 109/l) 61 (56%) 62 (63%) 
         Normal count (150 – 450 x 109/l) 41 (38%) 31 (31%) 
        Thrombocytosis (>450 x 109/l) 7 (6%) 6 (6%) 
 
  
 n=107 n = 88 
C-reactive protein*     45 (1-542) 30.5(1-209)  
         Normal <10 mg/l 30 (27%) 18 (20.5%) 
         Borderline (10-20 mg/l) 8 (7%) 18 (20.5%) 
         Increased >20 mg/l 72 (66%) 52 (59%) 
    
  
* Median (Ranges)                   
  
 
 
Ninety-nine (89%) of the 111 patients had a repeat FBC and 88 (79%) patients 
had a repeat CRP. Repeat FBC and CRP were requested at the discretion of the 
clinicians and are usually done when there is an abnormal count or if the patient 
has not improved clinically. The median number of days for both the FBC and 
CRP to be repeated was 3 days. Comparing the first FBC and the repeat FBC the 
number of patients with an abnormal WCC increased from 18% to 23% and the 
number of those with thrombocytopenia increased from 56% to 63% with the 
median platelet count decreasing from 123x109/l to 92x109/l. The number of 
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patients with a high CRP increased from 73% to 79%. Overall there was a trend 
towards a decrease in platelet count and WCC, and an increase in the CRP. 
 
3.5 Fungal Isolates 
The common isolates identified among neonates with fungal sepsis were Candida 
parapsilosis (63) and Candida albicans (43) (Figure 5.1). Only 6 were caused by 
other species, 4 by C. glabrata and 2 by C. krusei. One patient had isolated two 
fungal species during the same episode of fungal sepsis that is a C. albicans and 
C. glabrata. The organisms were not cultured from the same blood specimen but 
cultured within 10 days of each other. The patient was treated with a combination 
of amphotericin B and fluconazole and survived. The combination therapy was 
used as C. albicans was repeatedly isolated from 3 cultures done at different 
times.  
 
Figure 5.1 Fungal species causing sepsis in neonates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56%
38%
4% 2% C. parapsilosis
C. albicans
C. glabrata
C. krusei
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3.6 Susceptibilities 
Among the commonly isolated species susceptibilities were available for 25 of the 
43 (58%). C. albicans isolates for both amphotericin and fluconazole and 41 of the 
63 (63%) C. parapsilosis isolates were available for amphotericin B and 40 of the 
63 (63%) for fluconazole (Table 3.4). One of the C. parapsilosis isolates did not 
have susceptibilities documented for fluconazole. Among the C. albicans species 
with susceptibility results available 100% were sensitive to amphotericin B and 
96% sensitive to fluconazole. Whereas for C. parapsilosis the susceptibility 
patterns among those with available susceptibility results were 93% for 
amphotericin B and 58% for fluconazole. 
 
Table 3.4 Susceptibilities of Fungal Species Isolates to Antifungals 
      Organism (n) Amphotericin B Fluconazole 
   
C. albicans  (25) 
  
     Susceptible 25(100%) 24 (96%) 
     Intermediate 0 (0%) 0 (0%) 
     Resistant 0 (0%) 1 (4%) 
   
C. parapsilosis (41) 
  
     Susceptible 38(93%) 23 (58%) 
     Intermediate 2 (5%) 9 (23%) 
     Resistant 1 (2%) 8 (20%) 
   
C. glabrata (3) 
  
     Susceptible 1 (33%) 3 (100%) 
     Intermediate 2 (67%) 0 (0%) 
     Resistant 0 (0%) 0 (0%) 
  
  
 
  
30 
 
3.7 Mortality  
Among the 111 patients that were reviewed 27 died before hospital discharge 
giving an all-cause mortality rate of 24% for patients diagnosed with Candida 
(Table 3.5). Twenty-one patients died within 14 days of being diagnosed with 
Candida; giving a case fatality rate of 19% (Table 3.6). Case fatality rates for C. 
albicans and C. parapsilosis were high at 23% and 16% respectively. Only 1 
patient among the 6 patients who were infected by C. glabrata and C. krusei 
demised.  
 
 
Table 3.5 All –Cause Mortality of Infants with Fungal Sepsis according to Species 
Organism Number All cause 
mortality 
All-cause 
mortality 
 
   
C. albicans 43 13 30% 
 
   
C. parapsilosis 63 13 20% 
 
   
C. glabrata  4 0 0% 
 
   
C. krusei 2 1 50% 
    
Total 112* 27 24% 
        
* one patient had cultured 2 organisms 
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Table 3.6 Mortality of Infants with Fungal Sepsis 
Organism Number 
Candida -
related 
mortality 
Case 
fatality 
rates 
 
   
C. albicans 43 10 23% 
 
   
C. parapsilosis 63 10 16% 
 
   
C. glabrata  4 0 0% 
 
   
C. krusei 2 1 50% 
    
Total 112* 21 19% 
        
* one patient had cultured 2 organisms 
   
 
 
3.8 Comparing Survivors and Non-survivors in the Fungal Group 
Table 3.7 is a comparison between the characteristics of the survivors and non-
survivors in the fungal group for the deaths related to Candida sepsis. Comparing 
the survivors and non-survivors, the only difference noted was that the non-
survivors were older (18 days vs 15 days, p=0.04) and had lower platelet counts 
(39x109/l vs 151x109/l, p=0.007) than the survivors at the time of onset of sepsis. 
There were no significant differences in the birthweight, gestational age, gender 
and mode of delivery and maternal HIV status identified between the two groups. 
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Table 3.7 Comparison of the Characteristics Between the Survivors and Non-  
                 Survivors within the Fungal Sepsis Group for Candida-related mortality 
  Survivors            Non-survivors        p-value 
  n=81 n=21   
 
   Birth Weight (g)* 1300 (660- 3300) 1145 (820-3200) 0.7 
 
   Gestational age (weeks) *  30 (23 – 39) 29 (26- 40) 0.6 
 
   Booked 
  
0.104 
     Yes 69 14 
 
     No  9 5 
 
     Unknown  3 2 
 
 
   Gender 
  
0.245 
     Female 38 7 
 
     Male 42 14 
 
     Ambiguous 1 
  
 
   Mode of  Delivery 
  
0.492 
        Vaginal 49 11 
 
        Abdominal 27 5 
 
 
   Maternal HIV status 
  
0.87 
        Positive 25 6 
 
        Negative 47 7 
 
        Unknown 9 1 
 
 
   Age at onset (days)* 15 (1 – 60) 18 (2 -86) 0.04 
 
   Initial  n=80 n=21 
 WCC X 109/l* 12.45 (1.50-57.1) 13.5 (3.5-37.8) p=0.990 
Platelet count X109/l* 151.50 (5-755) 39 (5 – 422) p=0.007 
CRP mg/l* 37.2 (1- 542) 49 (2.2 -130 p=0.821 
 
   Repeat  n=73 n=18 
 WCC X 109/l*                      11.7 (2.69-37.4) 13.3 (4.4- 36.7) p=0.423 
Platelet count X109/l* 132.0 (9.0-721) 28 (4.0-331) p=0.002 
 n=14 n=66 
 CRP mg/l* 23.3 (1.00-209) 79.4 (4.0 – 200.2) p=0.013 
    
    
*Median (Ranges)    
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3.9 Comparison Between the C. albicans Group and the C. parapsilosis   
      Group 
In comparing the infants who were infected by C. albicans to those with C. 
parapsilosis, the only difference was that those that were infected with C. 
parapsilosis were smaller (p=0.022) and had a lower gestational age (p=0.002) 
than those infected with C. albicans (Table 3.8).  
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Table 3.8 Characteristics of Patients in the C. albicans group compared to the  
                C. parapsilosis group. 
Characteristic  C. albicans C. parapsilosis p-value 
 n=  43 n=  63   
 
Birthweight (g)* 
 
1594.65 (850-3200) 
 
1335.80 (660-3300) 
 
0.022 
    
Gestational age (weeks)* 32.20 (26.0-40.0) 30.04 (23.0-39.0) 0.002 
 
Booking status   0.848 
       Yes  35 50 
        No 7 9 
        Unknown 1 4 
    
HIV status   0.119 
     Positive 15 16 
     Negative 18 39 
     Unknown 10 7 
    
Mode of delivery   0.136 
     Vaginal 29 23 
     Abdominal 10 34 
   
Gender   0.272 
       Male 21 37 
       Female 22 25 
       Ambiguous  1 
    
Apgar     
      1 minute* 6 (1-10)   6 (1-9) 0.962 
      5 minute * 8 (4-10)     7 (4-10) 0.443 
    
Age at onset (days)*  20 (2-86) 18 (1-66) 0.61 
Death    0.316 
      Yes 10 10 
       No 29 47 
      
*Median (Ranges) 
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Table 3.9 Comparison of Initial and Repeat Blood Results Between the  
                C. albicans and the C. parapsilosis Group 
  
C. albicans C. parapsilosis p-value 
Initial n=41 n=63  
WCC x109/l* 13.0 (1.50-30.9) 14.8 (3.5-37.8) 0.61 
 n=41 n=63  
Platelet count x109/l* 136.8 (5.0-422.0) 179.7 (13.0-755.0) 0.162 
 
   
 n=43 n=62  
CRP mg/l 63.7 (2.0-191.0) 53.5 (1.0-542.0) 0.463 
        
   
   
Repeat    
WCC x109/l* n=38 n=56  
15.8 (8.3-22.1) 13.2 (8.2-15.6) 0.143 
  
 
 n=38 n=56  
Platelet count x109/l* 147.9 (27.0-210.0) 144.2 (32.0-232.0) 0.912 
 n=29 n=54  
CRP mg/l 62.2 (18.5-101.2) 40.9 (11.0-49.0) 0.031 
      
  
*Median (Ranges) 
   
 
 
 
There was no organism specific difference between the initial and repeat FBC with 
respect to the white cell count and platelets. However, there was a significant 
difference in the repeat CRP between the two groups with the C. albicans group 
having a much higher CRP count (p=0.031) (Table 3.9). 
 
3.10 Risk Factors Associated with the Development of Fungal Sepsis 
To determine the risk factors associated with development of fungal sepsis; a 
comparison was made between the study group and a convenient sample of 
infants infected with Gram-negative (GN) organisms. There was a significant 
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difference in birthweight, gestational age and day of life of onset of sepsis between 
the two groups. The fungal sepsis group weighed less (p=0.002), and had a lower 
gestational age (p=0.03) but a later day of onset of sepsis (p=<0.01) and had 
lower Apgar scores at 1 min (p=0.044) and 5 min (p=0.048) when compared to the 
GN group (Table 3.10).  
 
Table 3.10 Comparison of Characteristics of Infants with Fungal Sepsis  to those  
                   with Bacterial Sepsis. 
Characteristic Fungal Bacterial p-value 
 
n=111 n=112 
 
 
Birthweight *                            
 
1280 9660-330) 
 
1480 (780-3980) 
 
0.002 
Gestational Age*   30 (23 - 40) 32(25-42) 0.003 
Day of life onset*   16 (1-86) 8 (1-90) <0.001 
Apgar                                           
 
 
   1 minute*     7 (1-10) 8 (1-10) 0.044 
   5 minutes*   8 (4-10) 9 (3-10) 0.048 
Maternal HIV status   n = 93 n=104 0.156 
    Positive    31(33%) 46 (44%)  
    Negative  62 (67%) 58 (56%)  
Gender    0.303 
    Female 49 44  
    Male                 61 75  
Mode of delivery  0.677 
    Vaginal  66 82  
    Abdominal            35 37  
Deaths related to sepsis 21 (19%) 28 (23%) 0.670 
   
      
*Median (Ranges) 
 
In comparing the laboratory results the WCC was significantly lower (p<0.001) 
in the bacterial group in both the initial and repeat blood results. The platelet 
count and CRP were similar between the two groups at the time of the sepsis 
work-up, however, on the repeat FBC; the platelet count was significantly lower 
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(p=0.013) and the CRP (p=0.013) was significantly higher in the bacterial 
group. There was no statistically significant difference in mortality rate due to 
sepsis between the two groups (Table 3.11). 
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Table 3.11 Comparison of Initial and Repeat Laboratory Parameters Between 
                   Infants with Fungal and Bacterial Sepsis  
  Fungal Bacterial p- value 
Initial  blood results 
   
 n  = 109 n = 120 
 White cell count*   13.3 (1.5 -57.1) 8.8( 0.8-33.3) <0.001 
      Leucopaenia (<5x109/l)                                                                    7 (6%) 32 (27%) 
 
      Normal WCC (5–25x109/l )                                                           89 (82%) 85 (71%) 
 
      Leucocytosis (>25x109/l))      13 (12%) 4 (3%) 
 
 
   
 n = 109 n  = 120 
 Platelet count*         122 (5-755) 97 ( 5-510) 0.181 
      Thrombocytopaenia (<150x109/l)                                                    61 (56%) 78 (65%) 
 
      Normal (150–450x109/l) 41 (38%) 41 (34%) 
 
      Thrombocytosis (>450x109/l)  7 (6%) 1 (1%) 
 
 
   
 n = 107 n = 100 
 C-reactive protein*                  43(1-542) 33.5 (1-314) 0.641 
      Normal (<10 mg/l) 30 (27%) 27 (27%) 
 
      Borderline (10-20 mg/l)    8 (7%) 14 (14%) 
 
      Increased (>20 mg/l)    72 (66%) 59 (59%) 
 
 
   Repeat blood results 
   
 n = 99 n = 73 
 White cell count*   12.8(2.6-43.5) 8.6 (1.19-31.5) <0.001 
      Leucopaenia (<5 x 109/l)                                                                    10 (10%) 17 (23%) 
 
      Normal WCC (5 – 25 x 109/l )                                                           76 (77%) 49 (67%) 
 
      Leucocytosis (>25 x 109/l)) 13 (13%) 7 (10%) 
 
                  
   
 n = 99 n = 72 
 Platelet count*   92 ( 4-721) 45 (7 -393) 0.013 
      Thrombocytopaenia (<150x109/l)                                                    62 (63%) 58 (81%) 
 
      Normal (150– 450x109/l) 31 (31%) 14 (19%) 
 
      Thrombocytosis (>450x109/l)  6 (6%) 0 (0%) 
 
 
   
 n = 88 n = 40 
 C-reactive protein* 30.5(1-209) 72 ( 1-296) 0.013 
      Normal (<10 mg/l) 18 (20.5%) 5 (12.5%) 
 
      Borderline (10-20 mg/l)    18 (20.5%) 5 (12.5%) 
 
      Increased (>20 mg/l)    52 (59%) 30 (75%) 
 
        
*Median (Ranges) 
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There were more patients on antibiotics other than Penicillin G and Gentamicin 
(p=<0.001), who had central lines inserted (p=<0.001) and who were on TPN 
(p=<0.001) in the fungal sepsis group compared to the bacterial group (Table 
3.12). 
 
 
Table 3.12 Comparison of use of Antibiotics, Central lines, and TPN  
                    Between Infants with Fungal and Bacterial Sepsis  
  Fungal Bacterial p-value 
  n=111(%) n=122(%)   
 
First line antibiotics 
      Penicillin + Gentamicin 31(28) 60(49) p=0.0018 
 
   
 
Antibiotic other than first line 79 (71) 29 (24) <0.001 
     Tazocin + amikacin 41(37) 13 (11) 
 
     Meropenem + vancomycin 34 (31) 13 (11) 
 
     Other 4 (3) 3 (2) 
  
  
 
Central lines 62 (56) 38 (31) <0.001 
 
  
 
Total parenteral nutrition 85 (76) 24 (20) <0.001 
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CHAPTER 4 
4. DISCUSSION 
 
The advances made in newborn care have resulted in the premature neonate 
surviving longer and hence prone to interventions and nosocomial infections. 
Fungal sepsis is emerging as an important cause of sepsis in the neonatal 
population. One study found an eleven-fold increase in the rate of candidemia.23 
Candida species rank as the third and fourth most common organisms isolated in 
the neonatal units in the UK and in the USA respectively.104 There are few studies 
on epidemiology of fungal sepsis from developing countries like South Africa. This 
study was undertaken to determine the epidemiology of Candida infections at the 
Chris Hani Baragwanath Hospital.  
 
The main findings from this study were that 1. the common Candida species 
causing sepsis in neonates is Candida parapsilosis, 2. the common presenting 
signs in infants with fungal sepsis are apnoea, respiratory distress and non-
specific signs like temperature instability and lethargy, 3. the common clinical 
diagnosis is necrotizing enterocolitis 4. thrombocytopaenia and a high CRP are 
found in majority of patients with fungal sepsis, 5. Candida sepsis is associated 
with high mortality, 6. Thrombocytopaenia and a high CRP are associated with a 
high mortality, 7. patients with lower birth weight/ gestational age, prolonged 
hospital stay, low Apgar scores, who have a central venous catheter, TPN and 
have been treated with Cephalosporins are at risk of having fungal sepsis, 8. In 
contrast to the common notion that thrombocytopaenia is a sign of fungal sepsis 
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rather than bacterial sepsis, in this study the findings are that thrombocytopaenia 
is equally common to both bacterial and fungal infected neonates.  
 
Studies reported a higher prevalence in the ELBW and VLBW group.24,49 There 
was also an inverse relationship between gestational age and the acquisition of 
fungal sepsis. Benjamin et al reported that fungal sepsis is more common if the 
patient’s gestational age was < 25 weeks.10 In our study the median gestational 
age was 30 weeks and the birth weight 1500g, which is higher than that reported 
by Benjamin et al. This difference is accounted for by policies in the unit at the 
time of the study, where mechanical ventilation was not offered to neonates 
<1000g. Hence, patients did not live long enough to develop fungal sepsis. The 
smaller neonates being handled more due to nursing care and blood taking are 
more prone to infections. This coupled with the immature immune system and thin 
skin barrier make them more susceptible to nosocomial infections.7 In addition our 
hospital is a very busy neonatal facility with an average of 3500 admissions per 
year during the study period. Inadequate hand hygiene techniques could have 
contributed to the increase in C. parapsilosis in our setting. The literature has 
identified the hands of health care workers as a source.27,32,35 The median age of 
onset is 16 days. Saiman et al reported a median age of onset of 14 days for 
fungal colonisation, and another study documented a mean age of onset for fungal 
sepsis that ranged from 15 – 33 days similar findings to our study.7,35  
 
Central venous catheters, TPN and third generation cephalosporins have been 
identified as risk factors for the development of fungal sepsis in this study. These 
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findings are similar to other studies. Saiman et al identified similar risk factors in 
addition to the number of days the CVC was left in-situ, the use of H2 – blockers, 
and whether the patient was ventilated or not.35 Colonisation was also a risk factor 
identified as this would increase the likelihood to develop fungal sepsis.62,84,112,113 
Factors that Chow et al identified that selected for NAC organisms were the 
receipt of fluconazole, the insertion of CVCs and the use of antimicrobials.40 Abi 
Said et al also reported an increase in C. parapsilosis which was associated with 
the use of the use of TPN and CVCs.22  
 
Candida parapsilosis was the commonest organism isolated. There were no 
significant differences in the risk factors between the infants who infected with C. 
parapsilosis compared to the infant infected with C. albicans. Some studies have 
reported C. albicans as the common organism.35,51,52,80,114 The patients with C. 
parapsilosis were smaller and had a lower gestational age than the patients with 
C. albicans. This is similar to the findings by Shoa et al.100 
 
Thrombocytopenia occurs in 20-50% of all neonates admitted to the NICU and the 
incidence is 50% among preterm infants.115 Thrombocytopenia is used as a non-
specific marker for sepsis in the neonate.116 This study showed that patients 
infected with GN organisms had lower platelet counts than patients with fungal 
sepsis. Guida et al reported similar findings but used a cut-off of <100000x109/l to 
define thrombocytopenia.62 We used a platelet count of <150000x109/l in the 
definition of thrombocytopenia. Bhat et al found a lower platelet count in their GN 
group of patients.115 They also identified that K.pneumoniae was the organism that 
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caused the most effect on the platelet count. This is due to a lipopolysaccharide 
component, Lipid A which amplifies the interaction between the IgG Fc receptor 
and the organism and this causes a further increase in platelet consumption. A 
similar mechanism has been proposed for fungal sepsis but has not been 
identified. Another study found no difference in the platelet counts between the GN 
and gram positive and fungal organisms.117 However, this study did not look at the 
severity or duration of the thrombocytopenia. These may be important 
characteristics. Benjamin et al reported Candida organisms to be most associated 
with thrombocytopenia and formed part of his clinical predictive model.10 The other 
factors that could cause thrombocytopenia such as maternal steroids, pre-
eclampsia, maternal diabetes, maternal ITP were not assessed in this study.  
 
All of the C. albicans isolates were sensitive to fluconazole and amphotericin B. 
The Sentry antimicrobial surveillance programme in the USA reported that 95% of 
the C. albicans isolates were sensitive to amphotericin B.93 Whilst the TSARY 
surveillance programme in Taiwan reported an increase in resistance of all 
isolates to amphotericin B from 0.5% in 1999 to 2.5% in 2002 and a decrease in 
the resistance rate to fluconazole from 8.45 to 1.9%.79 Yet there were only 3 of the 
395 isolates of C. albicans resistant to amphotericin B in TSARY 2002.106 Amongst 
the C. parapsilosis isolates 93% were susceptible to amphotericin B and 20% 
were documented to have resistance to fluconazole. This is consistent with the 
findings in the Artemis Disk antifungal surveillance programme were 20.3% of C. 
parapsilosis isolates from South Africa were resistant to fluconazole.27 The region 
with the most susceptible isolates was found in Europe.  Clerihew et al reported 
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that all the C. parapsilosis to be sensitive to amphotericin B.36  The C. glabrata 
isolates were all sensitive to fluconazole and two-thirds showed a susceptible 
dose-dependent (S-DD) susceptibility profile to amphotericin B. Many studies are 
reporting an emerging resistance of C. glabrata and C. krusei to both antifungals 
and the IDSA guidelines recommend a higher dose of these drugs when treating 
these two isolates.63,102 Fluconazole prophylaxis selects for the isolation of these 
organisms hence, when treating patients with these two isolates an appropriate 
antifungal and dose should be commenced. During the period at which the data 
from this study was collected, fluconazole was not prescribed for prophylaxis. The 
one C. krusei isolate in this study was sensitive to amphotericin B and had 
intermediate resistance to fluconazole. This is in contrast to studies where C. 
krusei is resistant to fluconazole and having decreased susceptibility to 
amphotericin B.95,118 The significance of these findings is difficult to interpret as 
there were only two isolates of C. krusei. 
 
Fungal sepsis has a mortality rate of 20 – 40% with the rate being higher in the 
ELBW (37 – 40%) as compared to the VLBW infant (32%).47,51 Candida albicans 
had a higher mortality than C. parapsilosis in this study. This is similar to findings 
reported by Kauffmann et al where mortality of C. albicans vs C. parapsilosis, was 
44% vs 16% respectively. Stoll and Saiman et al had similar findings.8,9,35,109 The 
higher mortality associated with C. albicans infection is due to the organism’s 
virulence factors. It tends to adhere tighter to epithelial cells than C. parapsilosis 
and causes a more lethal clinical presentation.31 Whilst C. parapsilosis is less 
virulent it is more difficult to eradicate and this compounds the morbidity related to 
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this isolate. Other studies found no difference in mortality between the two 
organisms.36  Thrombocytopenia is associated with death in patients with Candida 
sepsis.26,115 It was reported by Bhat and colleagues that mortality was higher; 36% 
compared to 16% in patients with thrombocytopenia as compared to patients 
without thrombocytopenia. In this study a significant difference in platelet count 
was found in the repeat blood count between the survivors and non-survivors. 
Non-survivors had a much lower platelet count than the survivors. Candida 
albicans has emerged as the organism with the highest case fatality rate despite 
being the second commonest organism isolated. Fluconazole prophylaxis in a 
select group of patients would alter the prevalence of this organism and thereby 
decrease the overall mortality rate.  A randomised control trial would need to be 
performed in the unit as detailed by Kauffmann as this may alter the epidemiology 
of fungal sepsis in the neonatal unit. We should then be aware that the prevalence 
of the NAC may increase and alter the susceptibility profiles of the organisms. The 
unit policy has subsequently changed where ventilation is offered to neonates < 
1000g. This will influence the survival of neonates in our setting and influence the 
epidemiology of candidemia.   
 
The study identified the subset of patients that would develop fungal infections. In 
our setting if a VLBW had risk factors such as having had central lines, been on 
TPN and third generation cephalosporins and had abdominal surgery; we would 
empirically start antifungal treatment. Thrombocytopenia is not a pathognomonic 
feature as patients with GN sepsis would also present with a low platelet count62. It 
would be more important to look at the persistence of the thrombocytopenia and to 
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compare the nadir of the low platelet count.  Thrombocytopenia is commonly used 
to identify patients with fungal sepsis but from this study thrombocytopenia was 
not exclusively associated with fungal sepsis. These patients should be treated 
with antibacterials first and in cases where patients are not responding antifungal 
treatment should be considered.  
 
At present the choice of antifungals need not be altered as the resistance of the 
commoner isolates is not posing a serious problem. Trends need to be followed 
via a surveillance programme so as to identify emerging resistance as is seen in 
the rest of the world. This would then have an impact on future prescribing 
practices. 
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CHAPTER 5  
CONCLUSION 
In conclusion the VLBW and smaller infant are more prone to developing fungal 
sepsis. A lower platelet count is associated with an increased mortality. Having 
risk factors like the use of TPN, a CVC in-situ and a third generation cephalosporin 
places the VLBW infant at higher risk for fungal sepsis.  Great benefit will be 
gained if a surveillance programme is undertaken. Fungal sepsis is a major cause 
of infection and its associated mortality in neonates born or admitted at Chris Hani 
Baragwanath Hospital.  Its epidemiology is similar to what has been reported in 
other studies. Clinicians need to monitor development of resistance to fluconazole 
as some Candida species like C. parapsilosis have been found to be resistant to 
fluconazole.  
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CHAPTER 6 
LIMITATIONS 
This was a retrospective study hence many patient records were not located. The 
data collection was biased as to what had been written in the patient files. A 
convenient sample of patients with GN sepsis was used as a comparison to 
identify risk factors. Hence, they were not matched controls. Furthermore, the GN 
group was collected over a one year period and the fungal group over a three year 
period. It would have been ideal to get controls from patients who were not 
infected.  
 
With regard to the laboratory parameters, not all the patients had repeat laboratory 
markers performed. Had this been a prospective study we would have had 
increased numbers of repeat specimens and this could alter the trends observed.  
No other causes for the thrombocytopenia were looked at eg. maternal steroids 
and preeclampsia or the possibility of a congenital infection. The other pitfall in this 
study included that we did not look at the duration and nadir of the 
thrombocytopenia and the change in platelet count from baseline (i.e. before the 
onset of sepsis).  
Risk factors that contribute to the development of fungal sepsis are many. We 
reported on three. We had not taken into account other risk factors such as 
colonisation rates among the VLBW infants, whether the infant had been 
ventilated or not, if there was any abdominal surgery and if the neonate had 
received any steroids or H2 blockers. The number of days that the CVC had been 
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in-situ is another important factor and if the CVC was removed and how this 
affected clearance rates of the fungal isolate. 
Susceptibilities for all the organisms were not routinely done by the laboratory at 
the time, therefore, only two-thirds of the isolates had susceptibilities documented. 
Hence, the susceptibility profile may be a bit skewed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
50 
 
BIBLIOGRAPHY 
1.  Neonatal and Perinatal Mortality: Country, Regional and Global Estimates. 
2006; Available at: http://www.who.int/making -pregnancy-
safer/publications/neonatal.pdf, 2010.  
2. The Partnership for Maternal Newborn and Child Health. Opportunities for 
Africa's newborns: Practical data, policy and programmatic support for neborn care 
in Africa. : WHO on behalf of the Partnershipfor Maternal Newborn and Child 
Health; 2006.  
3. United Nations Millennium Declaration. 2000; Available 
at:http://www.unicef.org/mdg/index_aboutthegoals.htm. Accessed April, 2010.  
4. Garcia-Prats JA, Cooper TR. The Critically Ill Neonate With 
Infection:Management Considerations in the Term and Preterm Infant. Seminars in 
Pediatric infectious Disease 2000;11(1):4-12.  
5. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in 
very-low-birth-weight infants. Clin Microbiol Rev 2004 Jul;17(3):638-80, table of 
contents.  
6. Higgins RD, Baker CJ, Raju TN. Executive summary of the workshop on 
infection in the high-risk infant. J Perinatol 2010 Jun;30(6):379-383.  
7. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in 
very-low-birth-weight infants. Clin Microbiol Rev 2004 Jul;17(3):638-80, table of 
contents.  
8. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Late-
onset sepsis in very low birth weight neonates: a report from the National Institute 
of Child Health and Human Development Neonatal Research Network. J Pediatr 
1996 Jul;129(1):63-71.  
9. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. 
Late-onset sepsis in very low birth weight neonates: the experience of the NICHD 
Neonatal Research Network. Pediatrics 2002 Aug;110(2 Pt 1):285-291.  
10. Benjamin DK,Jr, DeLong ER, Steinbach WJ, Cotton CM, Walsh TJ, Clark RH. 
Empirical therapy for neonatal candidemia in very low birth weight infants. 
Pediatrics 2003 Sep;112(3 Pt 1):543-547.  
11. Kapur R, Polin RA, Yoder MC. The Immune System, Developmental 
Immunology. In: Martin RJ, Fanaroff AA, Walsh MC, editors. Neonatal-Perinatal 
Medicine. 8th Edition ed. Philedelphia: Mosby, Elsevier; 2006. p. 761.  
  
51 
 
12. Garland JS, Uhing MR. Strategies to prevent bacterial and fungal infection in 
the neonatal intensive care unit. Clin Perinatol 2009 Mar;36(1):1-13.  
13. Butler KM, Baker CJ. Candida: an increasingly important pathogen in the 
nursery. Pediatr Clin North Am 1988 Jun;35(3):543-563.  
14. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 
Sep;20(3):485-506.  
15. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections 
in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003 
Nov;3(11):685-702.  
16. Hazen KC, Howell SA. Candida, Cryptococcus and other Yeasts of Medical 
Importance. In: Murray PR, Baron EJ, Jorgensen JH, Laundry ML, Pfaller MA, 
editors. Manual of Clinical Microbiology. 9th Edition ed. Washington, D.C.: ASM 
PRESS; 2007. p. 1764-1780.  
17. Edwards MS. Fungal And Protozoal Infections. In: Martin RJ, Fanaroff AA, 
Walsh MC, editors. Neonatal-Perinatal Medicine. 8th Edition ed. Philedelphia: 
Mosby, Elsevier; 2006. p. 830.  
18. Edwards JEJ. Mycoses, Candida Species. In: Mandell GL, Bennett JE, Dolin 
R, editors. Principles nad Practices of Infectious Diseases. 6th Edition ed. 
Philedelphia: Elsevier, Chrchill, Livingstone; 2005. p. 2938-2951.  
19. Benjamin DK,Jr, Garges H, Steinbach WJ. Candida bloodstream infection in 
neonates. Semin Perinatol 2003 Oct;27(5):375-383.  
20. Chen SC, Marriott D, Playford EG, Nguyen Q, Ellis D, Meyer W, et al. 
Candidaemia with uncommon Candida species: predisposing factors, outcome, 
antifungal susceptibility, and implications for management. Clin Microbiol Infect 
2009 Jul;15(7):662-669.  
21. Nguyen MH, Peacock JE,Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, 
et al. The changing face of candidemia: emergence of non-Candida albicans 
species and antifungal resistance. Am J Med 1996 Jun;100(6):617-623.  
22. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The 
epidemiology of hematogenous candidiasis caused by different Candida species. 
Clin Infect Dis 1997 Jun;24(6):1122-1128.  
23. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive 
care unit: trends during fifteen years and clinical features of 111 cases. Pediatr 
Infect Dis J 1998 Jun;17(6):504-508.  
  
52 
 
24. Presterl E, Daxbock F, Graninger W, Willinger B. Changing pattern of 
candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of 
Vienna, Austria. Clin Microbiol Infect 2007 Nov;13(11):1072-1076.  
25. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. 
International surveillance of bloodstream infections due to Candida species: 
frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 
in the United States, Canada, and South America for the SENTRY Program. The 
SENTRY Participant Group. J Clin Microbiol 1998 Jul;36(7):1886-1889.  
26. Chen TC, Chen YH, Tsai JJ, Peng CF, Lu PL, Chang K, et al. Epidemiologic 
analysis and antifungal susceptibility of Candida blood isolates in southern 
Taiwan. J Microbiol Immunol Infect 2005 Jun;38(3):200-210.  
27. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, Colombo A, et al. 
Geographic and temporal trends in isolation and antifungal susceptibility of 
Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal 
Surveillance Program, 2001 to 2005. J Clin Microbiol 2008 Mar;46(3):842-849.  
28. Hobson RP. The global epidemiology of invasive Candida infections--is the 
tide turning? J Hosp Infect 2003 Nov;55(3):159-68; quiz 233.  
29. Odds FC. Candida infections: an overview. Crit Rev Microbiol 1987;15(1):1-5.  
30. Leibovitz E. Neonatal candidosis: clinical picture, management controversies 
and consensus, and new therapeutic options. J Antimicrob Chemother 2002 
Feb;49 Suppl 1:69-73.  
31. Bendel CM. Colonization and epithelial adhesion in the pathogenesis of 
neonatal candidiasis. Semin Perinatol 2003 Oct;27(5):357-364.  
32. van Asbeck EC, Huang YC, Markham AN, Clemons KV, Stevens DA. Candida 
parapsilosis fungemia in neonates: genotyping results suggest healthcare workers 
hands as source, and review of published studies. Mycopathologia 2007 
Dec;164(6):287-293.  
33. Weems JJ,Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical 
manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992 
Mar;14(3):756-766.  
34. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal 
pathogen. Clin Microbiol Rev 2008 Oct;21(4):606-625.  
35. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin 
RT, et al. Risk factors for Candida species colonization of neonatal intensive care 
unit patients. Pediatr Infect Dis J 2001 Dec;20(12):1119-1124.  
  
53 
 
36. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Candida parapsilosis 
infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007 
Mar;92(2):F127-9.  
37. Rowen JL. Fungal Infections in the Neonatal Intensive Care Unit. Seminars in 
Pediatric Infectious Diseases 2001;12(2):107-114.  
38. Cheng MF, Yang YL, Yao TJ, Lin CY, Liu JS, Tang RB, et al. Risk factors for 
fatal candidemia caused by Candida albicans and non-albicans Candida species. 
BMC Infect Dis 2005 Apr 7;5(1):22.  
39. Cheng MF, Yang YL, Yao TJ, Lin CY, Liu JS, Tang RB, et al. Risk factors for 
fatal candidemia caused by Candida albicans and non-albicans Candida species. 
BMC Infect Dis 2005 Apr 7;5(1):22.  
40. Chow JK, Yolan Y, Ruthazer R. Risk factors for albicans and non-albicans 
candidemia in the intensive care unit. Crit Care Med 2008;36(7):1993-1998.  
41. Samaranayake YH, Samaranayake LP. Candida krusei: biology, epidemiology, 
pathogenicity and clinical manifestations of an emerging pathogen. J Med 
Microbiol 1994 Nov;41(5):295-310.  
42. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, et al. 
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic 
and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 
2001 to 2005. J Clin Microbiol 2008 Feb;46(2):515-521.  
43. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida 
infections in the intensive care unit. Crit Care 2008;12(1):204.  
44. Fidel PL,Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, 
pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol 
Rev 1999 Jan;12(1):80-96.  
45. Askin DF. Bacterial and fungal infections in the neonate. J Obstet Gynecol 
Neonatal Nurs 1995 Sep;24(7):635-643.  
46. Benjamin DK,Jr, Garges H, Steinbach WJ. Candida bloodstream infection in 
neonates. Semin Perinatol 2003 Oct;27(5):375-383.  
47. Kaufman D. Fungal infection in the very low birthweight infant. Curr Opin Infect 
Dis 2004 Jun;17(3):253-259.  
48. Chapman RL. Candida infections in the neonate. Curr Opin Pediatr 2003 
Feb;15(1):97-102.  
  
54 
 
49. Chapman RL, Faix RG. Invasive neonatal candidiasis: an overview. Semin 
Perinatol 2003 Oct;27(5):352-356.  
50. Chapman RL. Prevention and treatment of Candida infections in neonates. 
Semin Perinatol 2007 Feb;31(1):39-46.  
51. Shetty SS, Harrison LH, Hajjeh RA, Taylor T, Mirza SA, Schmidt AB, et al. 
Determining risk factors for candidemia among newborn infants from population-
based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J 2005 
Jul;24(7):601-604.  
52. Feja KN, Wu F, Roberts K, Loughrey M, Nesin M, Larson E, et al. Risk factors 
for candidemia in critically ill infants: a matched case-control study. J Pediatr 2005 
Aug;147(2):156-161.  
53. Brecht M, Clerihew L, McGuire W. Prevention and treatment of invasive fungal 
infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2009 
Jan;94(1):F65-9.  
54. Baley JE, Kliegman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the 
very low birth weight infant. Pediatrics 1986 Aug;78(2):225-232.  
55. Huang YC, Li CC, Lin TY, Lien RI, Chou YH, Wu JL, et al. Association of 
fungal colonization and invasive disease in very low birth weight infants. Pediatr 
Infect Dis J 1998 Sep;17(9):819-822.  
56. Magny JF, Bremard-Oury C, Brault D, Menguy C, Voyer M, Landais P, et al. 
Intravenous immunoglobulin therapy for prevention of infection in high-risk 
premature infants: report of a multicenter, double-blind study. Pediatrics 1991 
Sep;88(3):437-443.  
57. Benjamin DK,Jr, Ross K, McKinney RE,Jr, Benjamin DK, Auten R, Fisher RG. 
When to suspect fungal infection in neonates: A clinical comparison of Candida 
albicans and Candida parapsilosis fungemia with coagulase-negative 
staphylococcal bacteremia. Pediatrics 2000 Oct;106(4):712-718.  
58. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK,Jr, et al. 
The association of third-generation cephalosporin use and invasive candidiasis in 
extremely low birth-weight infants. Pediatrics 2006 Aug;118(2):717-722.  
59. Karlowicz MG, Hashimoto LN, Kelly RE,Jr, Buescher ES. Should central 
venous catheters be removed as soon as candidemia is detected in neonates? 
Pediatrics 2000 Nov;106(5):E63.  
60. Linder N, Levit O, Klinger G, Kogan I, Levy I, Shalit I, et al. Risk factors 
associated with candidaemia in the neonatal intensive care unit: a case-control 
study. J Hosp Infect 2004 Aug;57(4):321-324.  
  
55 
 
61. Benjamin DK,Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. 
Neonatal candidiasis among extremely low birth weight infants: risk factors, 
mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 
2006 Jan;117(1):84-92.  
62. Guida JD, Kunig AM, Leef KH, McKenzie SE, Paul DA. Platelet count and 
sepsis in very low birth weight neonates: is there an organism-specific response? 
Pediatrics 2003 Jun;111(6 Pt 1):1411-1415.  
63. Pappas PG, Kauffman CA, Andes D, Benjamin DK,Jr, Calandra TF, Edwards 
JE,Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 
update by the Infectious Diseases Society of America. Clin Infect Dis 2009 Mar 
1;48(5):503-535.  
64. Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal 
therapy. Trans Am Clin Climatol Assoc 2008;119:197-215; discussion 215-6.  
65. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination 
treatment of invasive fungal infections. Clin Microbiol Rev 2005 Jan;18(1):163-194.  
66. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. 
Guidelines for treatment of candidiasis. Clin Infect Dis 2004 Jan 15;38(2):161-189.  
67. Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and 
polyenes. Lancet Infect Dis 2002 Sep;2(9):550-563.  
68. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob 
Chemother 2002 Feb;49 Suppl 1:31-36.  
69. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the 
differences? Clin Microbiol Infect 2008 May;14 Suppl 4:25-36.  
70. Juster-Reicher A, Leibovitz E, Linder N, Amitay M, Flidel-Rimon O, Even-Tov 
S, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal 
candidiasis in very low birth weight infants. Infection 2000 Jul-Aug;28(4):223-226.  
71. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, 
mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002 
Feb;49 Suppl 1:21-30.  
72. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz 
E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in 
neonates. Eur J Clin Microbiol Infect Dis 2003 Oct;22(10):603-607.  
73. Linder N, Klinger G, Shalit I, Levy I, Ashkenazi S, Haski G, et al. Treatment of 
candidaemia in premature infants: comparison of three amphotericin B 
preparations. J Antimicrob Chemother 2003 Oct;52(4):663-667.  
  
56 
 
74. Moreira ME. Controversies about the management of invasive fungal 
infections in very low birth weight infants. J Pediatr (Rio J) 2005 Mar;81(1 
Suppl):S52-8.  
75. Karlowicz MG. Candidal renal and urinary tract infection in neonates. Semin 
Perinatol 2003 Oct;27(5):393-400.  
76. Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. 
Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a 
prospective randomized trial. Pediatr Infect Dis J 1996 Dec;15(12):1107-1112.  
77. Driessen M, Ellis JB, Muwazi F, De Villiers FP. The treatment of systemic 
candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 1997 
Sep;17(3):263-271.  
78. De Rosa FG, Garazzino S, Pasero D, Di Perri G, Ranieri VM. Invasive 
candidiasis and candidemia: new guidelines. Minerva Anestesiol 2009 Jul-
Aug;75(7-8):453-458.  
79. Yang YL, Li SY, Cheng HH, Lo HJ, TSARY Hospitals. The trend of 
susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 
2002 in Taiwan. BMC Infect Dis 2005 Nov 3;5:99.  
80. Nakamura T, Takahashi H. Epidemiological study of Candida infections in 
blood: susceptibilities of Candida spp. to antifungal agents, and clinical features 
associated with the candidemia. J Infect Chemother 2006 Jun;12(3):132-138.  
81. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. 
Fluconazole prophylaxis against fungal colonization and infection in preterm 
infants. N Engl J Med 2001 Dec 6;345(23):1660-1666.  
82. Kaufman D. Strategies for prevention of neonatal invasive candidiasis. Semin 
Perinatol 2003 Oct;27(5):414-424.  
83. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice 
weekly fluconazole prophylaxis for prevention of invasive Candida infection in 
high-risk infants of <1000 grams birth weight. J Pediatr 2005 Aug;147(2):172-179.  
84. Manzoni P, Arisio R, Mostert M, Leonessa M, Farina D, Latino MA, et al. 
Prophylactic fluconazole is effective in preventing fungal colonization and fungal 
systemic infections in preterm neonates: a single-center, 6-year, retrospective 
cohort study. Pediatrics 2006 Jan;117(1):e22-32.  
85. Montravers P, Jabbour K. Clinical consequences of resistant Candida 
infections in intensive care. Int J Antimicrob Agents 2006 Jan;27(1):1-6.  
  
57 
 
86. Sarvikivi E, Lyytikainen O, Soll DR, Pujol C, Pfaller MA, Richardson M, et al. 
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused 
infections in a neonatal intensive care unit. J Clin Microbiol 2005 Jun;43(6):2729-
2735.  
87. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to 
prevent mortality and morbidity in very low birth weight infants. Cochrane 
Database Syst Rev 2007 Oct 17;(4)(4):CD003850.  
88. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to 
prevent mortality and morbidity in very low birth weight infants. Cochrane 
Database Syst Rev 2007 Oct 17;(4)(4):CD003850.  
89. Swoboda SM, Merz WG, Lipsetta PA. Candidemia: the impact of antifungal 
prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003 
Winter;4(4):345-354.  
90. Baddley J W, Pappas P G. Antifungal Combination Therapy. Drugs 
2005;65(11):1461-1480.  
(91) Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. 
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of 
America. Clin Infect Dis 2000 Apr;30(4):662-678.  
92. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: 
molecular mechanisms and clinical consequences. Lancet Infect Dis 2002 
Feb;2(2):73-85.  
93 Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, et al. Empiric 
therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 
1991 May-Jun;13(3):496-503.  
94. Marr KA. Empirical antifungal therapy--new options, new tradeoffs. N Engl J 
Med 2002 Jan 24;346(4):278-280.  
95. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. 
International surveillance of bloodstream infections due to Candida species: 
frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, 
and voriconazole of isolates collected from 1997 through 1999 in the SENTRY 
antimicrobial surveillance program. J Clin Microbiol 2001 Sep;39(9):3254-3259.  
96. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum 
MA, et al. Antifungal susceptibility testing: practical aspects and current 
challenges. Clin Microbiol Rev 2001 Oct;14(4):643-58, table of contents.  
97. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility 
testing. Clin Microbiol Rev 1993 Oct;6(4):367-381.  
  
58 
 
98. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical 
advances and potential clinical applications. Clin Infect Dis 1997 May;24(5):776-
784.  
99. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 
2002 Feb;49 Suppl 1:7-10.  
100. Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the 
treatment of invasive fungal infections. Int J Antimicrob Agents 2007 
Dec;30(6):487-495.  
101. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela 
M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream 
infection: results from population-based surveillance, barcelona, Spain, from 2002 
to 2003. J Clin Microbiol 2005 Apr;43(4):1829-1835.  
102. Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, et al. Distribution 
and antifungal susceptibility of Candida species causing candidemia from 1996 to 
1999. Diagn Microbiol Infect Dis 2004 Jan;48(1):33-37.  
103. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza 
SA, et al. Incidence of bloodstream infections due to Candida species and in vitro 
susceptibilities of isolates collected from 1998 to 2000 in a population-based active 
surveillance program. J Clin Microbiol 2004 Apr;42(4):1519-1527.  
104. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. 
Epidemiology, management, and risk factors for death of invasive Candida 
infections in critical care: a multicenter, prospective, observational study in France 
(2005-2006). Crit Care Med 2009 May;37(5):1612-1618.  
105. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida 
species and distribution of species recovered from blood cultures over a 5-year 
period. Antimicrob Agents Chemother 1994 Jun;38(6):1422-1424.  
106. Yang YL, Li SY, Cheng HH, Lo HJ, TSARY Hospitals. Susceptibilities to 
amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn 
Microbiol Infect Dis 2005 Mar;51(3):179-183.  
107. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: 
pathogenicity and antifungal resistance. J Hosp Infect 2002 Apr;50(4):243-260.  
108. Faix RG, Chapman RL. Central nervous system candidiasis in the high-risk 
neonate. Semin Perinatol 2003 Oct;27(5):384-392.  
109. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD 
Neonatal Research Network. Semin Perinatol 2003 Aug;27(4):293-301.  
  
59 
 
110. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. 
Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003 Nov 
1;37(9):1172-1177.  
111. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A 
prospective observational study of candidemia: epidemiology, therapy, and 
influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 
2003 Sep 1;37(5):634-643.  
112. Manzoni P, Farina D, Leonessa M, d'Oulx EA, Galletto P, Mostert M, et al. 
Risk factors for progression to invasive fungal infection in preterm neonates with 
fungal colonization. Pediatrics 2006 Dec;118(6):2359-2364.  
113. Kaufman DA, Gurka MJ, Hazen KC, Boyle R, Robinson M, Grossman LB. 
Patterns of fungal colonization in preterm infants weighing less than 1000 grams at 
birth. Pediatr Infect Dis J 2006 Aug;25(8):733-737.  
114. Huang YC, Lin TY, Lien RI, Chou YH, Kuo CY, Yang PH, et al. Candidaemia 
in special care nurseries: comparison of albicans and parapsilosis infection. J 
Infect 2000 Mar;40(2):171-175.  
115. Bhat MA, Bhat JI, Kawoosa MS, Ahmad SM, Ali SW. Organism-specific 
platelet response and factors affecting survival in thrombocytopenic very low birth 
weight babies with sepsis. J Perinatol 2009 Oct;29(10):702-708.  
116. Akarsu S, Taskin E, Kilic M, Ozdiller S, Gurgoze MK, Yilmaz E, et al. The 
effects of different infectious organisms on platelet counts and platelet indices in 
neonates with sepsis: is there an organism-specific response? J Trop Pediatr 2005 
Dec;51(6):388-391.  
117. Manzoni P, Mostert M, Galletto P, Gastaldo L, Gallo E, Agriesti G, et al. Is 
thrombocytopenia suggestive of organism-specific response in neonatal sepsis? 
Pediatr Int 2009 Apr;51(2):206-210.  
118. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, SENTRY 
Participants Group. Trends in antifungal susceptibility of Candida spp. isolated 
from pediatric and adult patients with bloodstream infections: SENTRY 
Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002 
Mar;40(3):852-856.  
 
 
 
 
  
60 
 
 
APPENDIX A 
  
61 
 
  
62 
 
  
63 
 
 
  
64 
 
 
  
65 
 
 
  
66 
 
 
  
67 
 
 
  
68 
 
 
  
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
70 
 
  
71 
 
 
DATA COLLECTION SHEET: FUNGAL SEPSIS 
1. Infant details 
ID Number: …………………………………………………….. 
Culture date:     ......./……./……. ;         Episode (No): ……. ;     Ward: ………. ;     Admission date: 
……./……./……. 
Patient’s Hosp No: ……………………………………………………… ;     Date of Birth: ……./……./……. 
Place of Birth: ………… (1=Bara, 2=Clinic, 3=Home, 4=Other Hosp) 
Birthwt: ………. ;     GA: ………. ; (Based o Obstets/Paeds): ……… ;  Sex: …….. ;    Race: ……………….. ; 
Apgar: 1’…../5’…….. 
Mode of delivery:      C/S, NVD, Forceps, Vacuum 
Maternal HIV status: Pos / Neg / Unknown 
 
2. Presentation 
Date of onset of symptoms: ……./……./……. ;                  Day of life at onset: …………………………….. 
Symptoms (Reason for sepsis work up): 
……………………………………………………………………………………………………………………….. 
Diagnosis: ………………………………………………………………………………………… 
Antibiotics started on (date): ………………………………………………………….. 
Previous antibiot. Stopped: ……./……./……. 
Date previous antibiot. Stopped: ……./……./……. 
Ventilated:  Yes / No; If Yes, Date intubated: ……./……./……. ;  Date extubated: ……./……./……. 
On Oxygen Headbox / Cannulae: Yes / No 
Central line: Yes / No;  Type: UAC/UVC/Other;  Date inserted: ……./……./……. ;   Date removed: 
……./……./……. 
Peripheral line: Yes / No 
TPN:  Yes / No,    If yes, Date started, ……./……./……. ‘  Intralipids:  Yes / No 
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FBC done with sepsis w/u:    Wbc: …….   Hb: ……. Plts: ……. (Date of FBC: ……./……./……. ) 
Diff Count:  Neutr…….;  Lymph: ……..;  Mono: …….;  Eos: ……;  Baso: …….  Others: …………….. 
Smear results: 
………………………………………………………………………………………………………………………………………………… 
CPR done with sepsis w/u: ………. 
CSF done with or around time of sepsis w/u:  Yes / No; If Yes , date CSF done: ……./……./……. 
CSF Results:  Polys: …………;  Lymphs: ……….; Rbcs: ……….;  Protein: ……….;  Gluc: ……….;  CI: ………. 
FBC immed. After sepsis w/u:      Wbc: ……….  Hb: ………. Plts: ……….  (Date of FBC: ……../……../…….. 
Diff Count:  Neutr ……….;  Lymph:……….;  Mono: ……….;  Eos: ……….  Baso:……….  Others: ………. 
Smear results: 
………………………………………………………………………………………………………………………………………………… 
Repeat CRP done: …………………. 
CSF Repeated:  Yes / No;  If Yes, date CSF repeated: ………/………./………. 
CSF Results:  Polys: ……….;  Lymphs: ……….;  Rbcs: ……….;  Protein: ……….;  Gluc:……….;  CI:………. 
 
3. Organism and susceptibilities 
Organism 1: ………………………………………………………………………….; 
Culture Site:  Bld / CSF 
If fungal, Sensitivity: Fluconazole – R/S;  Amphotericin B-R/S 
Organism 2: ………………………………………………………………………….; 
Culture Site: Bld / CSF 
If fungal, Sensitivity:  Fluconazole- R/S; Amphotericin B- R/S 
 
Culture repeated:  Yes / No; Date culture repeated: ………../………/………;  Repeat culture: Positive / 
Negative 
If culture positive, Organism: ………………………………………………..; 
If fungal, Sensitivity: Fluconazole – R/S; Amphotericin B- R/S 
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4. Outcome 
Died: Yes / No;  If died, date of death: ………/………./………. 
Cause of death: ……………………………………………………………………………………………………………………………. 
Postmortem:  Yes / No;  If done, diagnosis after postmortem:…………………………………………………….. 
Other Comments:…………………………………………………………………………………………………………………………. 
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